Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.57 |
| ▸ | RAF1 | P04049 | 11/20 | 0.56 |
| ▸ | BRAF | P15056 | 10/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239151 | 0.83 | KDR (0.66) | KDRRAF1BRAFPDGFRBMAPT | |
| SCHEMBL14433880 | 0.76 | ALDH1A1 (0.67) | MAPTLMNATP53KMT2A | |
| SCHEMBL12858514 | 0.76 | MAPT (0.74) | KDRMAPTLMNACSF1RKIT | |
| SCHEMBL15238534 | 0.76 | RAF1 (0.54) | RAF1BRAFMAPTLMNAKMT2A | |
| SCHEMBL2304413 | 0.74 | TTR (0.51) | LMNAKMT2A | |
| SCHEMBL29071250 | 0.74 | MAPT (0.67) | KDRMAPTLMNACSF1RKIT | |
| SCHEMBL20467572 | 0.73 | MAPT (0.70) | KDRMAPTLMNACSF1RKIT | |
| SCHEMBL1264375 | 0.73 | MAPT (0.74) | KDRMAPTLMNACSF1RKIT | |
| SCHEMBL12352571 | 0.73 | KDR (0.61) | KDRRAF1BRAFPDGFRBMAPT | |
| SCHEMBL14481034 | 0.73 | KDR (0.61) | KDRRAF1BRAFPDGFRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962637-B2 | Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors | DEBIOPHARM S.A. (CH) | 2015-02-24 | — | — | US | disclosed |
| US-8962637-B2 | Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors | DEBIOPHARM S.A. (CH) | 2015-02-24 | — | — | US | disclosed |
| EP-2536722-B1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM SA (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2536722-B1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM SA (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2013-06-06 | — | — | US | disclosed |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2013-06-06 | — | — | US | disclosed |
| US-8440679-B2 | Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors | DEBIOPHARM S.A. (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8440679-B2 | Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors | DEBIOPHARM S.A. (CH) | 2013-05-14 | — | — | US | disclosed |
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LTD. (IN) | 2013-01-10 | — | — | US | disclosed |
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LTD. (IN) | 2013-01-10 | — | — | US | disclosed |
| EP-2536722-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | Debiopharm S.A. (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101806-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101806-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | JAK2, SRC, JAK1 | KDR 663/4885RAF1 141/4885BRAF 73/4885 |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | JAK2, SRC, JAK1 | KDR 663/4885RAF1 141/4885BRAF 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.